Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens

Ron Ram, Hila Magen-Nativ, Liat Vidal, Corina Herscovici, Anat Peck, Pia Raanani, Ofer Shpilberg, Moshe Yeshurun

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Induction therapy in patients with multiple myeloma has evolved from chemotherapy-based to novel agents-based regimens. We compared autologous hematopoietic cell transplantation (HCT)-associated toxicity in patients induced with VTD-PACE (bortezomib, thalidomide, dexamethasone, cisplatinum, adriamycin, cyclophosphamide, and etoposide) to that of patients induced with novel agents-only therapy. Methods: We reviewed medical charts of all patients with multiple myeloma who were given induction therapy and HCT. Results: Between the years 2007 and 2011, 38 patients received VTD-PACE, and 31 patients received novel agents-only regimen. Mean time to neutrophil and platelets recovery was longer in patients given VTD-PACE compared with those given novel agents-only regimen (7 vs. 6 d, p = 0.0002 and 11 vs. 10 d, p = 0.04, respectively). We observed higher rates of grade 2-4 mucositis and parenteral narcotic analgesia administration in the patients given VTD-PACE (45% vs. 19%, p = 0.05 and 37% vs. 12%, p = 0.07, respectively). Progression free survival and overall survival were not statistically significantly different between the two groups. Conclusions: A more intensive induction regimen was associated with slightly delayed counts recovery and a higher rate of mucositis during HCT compared with novel agents-only regimens. A longer follow-up is needed to assess long-term disease control of the two different regimens.

Original languageEnglish
Pages (from-to)E549-E554
JournalClinical Transplantation
Volume26
Issue number5
DOIs
StatePublished - Sep 2012

Keywords

  • Autologous transplantation
  • Myeloma
  • Novel agents
  • Toxicity

Fingerprint

Dive into the research topics of 'Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens'. Together they form a unique fingerprint.

Cite this